DEPARTMENT OF HEALTH & HUMAN SERVICES

ANDA 76-162

Food and Drug Administration
Rockville MD 20857

OCT 14 2004

Teva Pharmaceuticals USA
Attention: Deborah Jaskot
U.S. Agent for: Pharmachemie B.V.
1090 Horsham Road
P.O.Box 1090
North Wales, PA 19454

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated April 16, 2001, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Carboplatin for Injection USP, packaged in 50 mg, 150 mg, and 450 mg single-dose vials.

Reference is made to the Tentative Approval letter issued by this office on January 14, 2003, and to your amendments dated February 16, April 15, and July 12, 2004.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Carboplatin for Injection USP, packaged in 50 mg, 150 mg, and 450 mg single-dose vials, to be bioequivalent and therapeutically equivalent to the listed drug (Paraplatin® for Injection, packaged in 50 mg, 150 mg, and 450 mg single-dose vials, respectively, of Bristol Myers Squibb Company Pharmaceutical Research Institute).

Under Section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy that you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FDA 2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

(b)(6)

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research